In the clinical trials for PD-1/PD-L1 inhibitors in TNBC, positivity was defined as PD-L1 level in the stroma or ≥ 1% of tumor cells in the KEYNOTE-012 trial (a 22C3 clone was used before the 22C3 Dako PharmDx IHC assay was available), a Combined Positive Score of ≥ 1 with the FDA-approved 22C3 Dako PharmDx IHC assay in the KEYNOTE-086 trial, and an immune cell score of ≥ 1% with the Ventana SP142 antibody in the IMpassion130 trial [12–14]. The gene discussed is CD274; the disease is neoplasm.